Linked Life Data

11781625

Source:http://linkedlifedata.com/resource/pubmed/id/11781625

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11781625rdf:typepubmed:Citationlld:pubmed
pubmed-article:11781625lifeskim:mentionsumls-concept:C1709854lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0005953lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0006463lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0184511lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0039593lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0022885lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:11781625lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:11781625pubmed:issue8lld:pubmed
pubmed-article:11781625pubmed:dateCreated2002-1-8lld:pubmed
pubmed-article:11781625pubmed:abstractTextIn order to control busulfan pharmacokinetic variability and toxicity, a specific monitoring protocol was instituted in our bone marrow transplant BMT paediatric patients including a test dose, daily Bayesian forecasting of busulfan plasma levels, and Bayesian individualization of busulfan dosage regimens. Twenty-nine children received BMT after a busulfan-based conditioning regimen. Individual pharmacokinetic parameters were obtained following a 0.5 mg*kg test dose and were used for daily individualization of dosage regimens during the subsequent 4-day course of treatment. Doses were adjusted to reach a target mean AUC per 6 h between 4 and 6 microg.h.ml(+1). Plasma busulfan assays were performed by liquid chromatography. Pharmacokinetic analysis used the USC*PACK software. The performance of the test dose to predict AUC during the busulfan regimen was evaluated. Incidence of toxicity, chimerism and relapse, overall Kaplan-Meier survival, and VOD-free survival were compared after matching our patients (group A) with patients conditioned by using standard doses of busulfan (group B). Busulfan doses were decreased in 69% of patients compared to conventional doses. Expected AUC was significantly correlated with observed AUC and predictability of the test dose was 101.9 +/- 17.9%. Incidence of VOD in group A was 3.4% vs 24.1% in group B, while the incidence of stomatitis was similar. Engraftment was successful in all patients in group A. The rate of full engraftment at 3 months post-BMT was higher in group A (P = 0.012). Long-term overall survival did not differ between the two groups, in contrast to the 90-day survival. VOD-free survival was higher in group A (P = 0.026). Pharmacokinetic monitoring and individualization of busulfan dosage regimen are useful in improving clinical outcome and reducing early mortality in paediatric bone marrow transplant recipients.lld:pubmed
pubmed-article:11781625pubmed:languageenglld:pubmed
pubmed-article:11781625pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11781625pubmed:citationSubsetIMlld:pubmed
pubmed-article:11781625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11781625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11781625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11781625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11781625pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11781625pubmed:statusMEDLINElld:pubmed
pubmed-article:11781625pubmed:monthOctlld:pubmed
pubmed-article:11781625pubmed:issn0268-3369lld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:SouilletGGlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:DasKKlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:MartinPPlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:MairePPlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:BertrandYYlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:JelliffeR WRWlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:BleyzacNNlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:AulagnerGGlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:GalambrunCClld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:MagronPPlld:pubmed
pubmed-article:11781625pubmed:authorpubmed-author:JanolyAAlld:pubmed
pubmed-article:11781625pubmed:issnTypePrintlld:pubmed
pubmed-article:11781625pubmed:volume28lld:pubmed
pubmed-article:11781625pubmed:ownerNLMlld:pubmed
pubmed-article:11781625pubmed:authorsCompleteYlld:pubmed
pubmed-article:11781625pubmed:pagination743-51lld:pubmed
pubmed-article:11781625pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:meshHeadingpubmed-meshheading:11781625...lld:pubmed
pubmed-article:11781625pubmed:year2001lld:pubmed
pubmed-article:11781625pubmed:articleTitleImproved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.lld:pubmed
pubmed-article:11781625pubmed:affiliationDepartment of Pharmacy, Debrousse Hospital, Lyon, France.lld:pubmed
pubmed-article:11781625pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11781625pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11781625lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11781625lld:pubmed